Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Abstract Background Chimeric antigen receptor CAR-T cell therapies have ushered in a new era of treatment for specific blood cancers, offering unparalleled efficacy in cases of treatment resistance or relapse. However, the emergence of cytokine release syndrome (CRS) as a side effect poses a challen...

Descripción completa

Detalles Bibliográficos
Autores principales: Na Zheng, Yihao Long, Zixuan Bai, Jianing Li, Hongyu Wang, Dan-Dan Song, Hong-Lin Liu, Jian-Hong Shi, Shuli Zhao
Formato: Artículo
Lenguaje:English
Publicado: BMC 2024-01-01
Colección:Journal of Translational Medicine
Materias:
Melatonin
Chimeric antigen receptors
Cytokine release syndrome
Cell- and tissue-based therapy
CD19 antigen
Adoptive immunotherapy
Acceso en línea:https://doi.org/10.1186/s12967-023-04779-z

Internet

https://doi.org/10.1186/s12967-023-04779-z

Ejemplares similares